This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in
subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor
B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an
expansion stage where participants will be enrolled into indication-specific cohorts.